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ABSTRACT
In allogeneic hematopoietic stem cell transplantation (AHSCT) graft-versus-host disease (GVHD) and graft-
versus-leukemia (GVL) effect are closely but not invariably linked.Thus, harnessing donor lymphocytemediated
GVL immunity and separating it from GVHD is of particular interest. Based on results obtained in murine
models we have explored the CD95-mediated activation-induced cell death (AICD) strategy to selectively
deplete alloreactivity in human donor T lymphocytes in vitro. Following stimulation of CD31 T cells isolated
from HLA-A*0201-positive donors with HLA or minor histocompatibility antigen mismatched hematopoietic
or nonhematopoietic cells in the presence of agonistic anti-CD95 antibody, we achieved efficient and selective
allodepletion across major and minor histocompatibility mismatched barriers. Residual alloreactivity was in
the range of 10% and 25% using hematopoietic cells and primary keratinocytes as alloantigen-presenting cells,
respectively. CD81 T cells specific for HLA-A*0201-associated cytomegalovirus (CMV), Epstein-Barr virus
(EBV), andWilms tumor 1 peptide epitopes were retained at significant numbers within the allodepleted donor
lymphocyte subsets. Additionally, CD41 FoxP31 regulatory T cells persisted after the allodepletion procedure.
Our results show that AICD induced by an agonistic anti-CD95 antibody might be useful to generate allode-
pleted donor lymphocyte products with preserved beneficial immune functions for patients undergoingAHSCT.
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Donor-derived T cells, either present in the stem-
cell graft or administered as donor lymphocyte
infusion (DLI), support engraftment [1], improve
immunity particularly to viral infections [2], and
confer potent graft-versus-leukemia (GVL) responses
after allogeneic hematopoietic stem cell transplantat-
ion (AHSCT) [3-5]. However, donor T cells are
also central mediators of graft-versus-host disease
(GVHD) [6,7], which remains a major complication
in AHSCT. Nonselective removal of donor T cells
effectively controls GVHD, but concurrently in-
creases the risk for opportunistic infections andabrogates therapeutically desired immune responses
toward leukemic cells. There has been accumulating
evidence suggesting that the GVL effect is closely
but not inseparably linked with the development of
GVHD [8,9] and distinct subsets of allogeneic T lym-
phocytes can confer GVL reactivity in the absence of
GVHD [10-12]. This is further supported by in vitro
studies demonstrating that donor T cells at the clonal
level can recognize antigens with either ubiquitous or
hematopoiesis-restricted tissue expression [13-15].
Therefore, separation and expansion of allogeneic T
cell specificities devoid of graft-versus-host (GVH)
reactivity to specifically promote GVL immune
100 U. F. Hartwig et al.responses remains of central interest for improving the
therapeutic outcome in AHSCT.
Various conceptually different strategies have been
developed to eliminate alloreactive donor T lympho-
cytes following exposure to allogeneic stimulator cells,
either in vivo by inducible ‘‘suicide’’ genes expressed in
genetically modified allogeneic T lymphocytes [16], or
ex vivo by photodynamic purging [17], by concomitant
costimulatory blockade [18], by fluorescence-activated
cell sorting [19], or by targeting activation-induced an-
tigens such as CD25 [20-22], CD69 [23,24], HLA-DR
[25], and CD137 [26]. Of those, CD25-based appro-
aches already demonstrated in vivo efficacy in terms of
GVHD reduction and graft survival in haploidentical
and HLA-identical AHSCT [27-29]. However, a con-
siderable number of these studies did not include
a detailed in vitro analysis on the persistence of antileu-
kemicTcells after the depletionmaneuver. In addition,
as CD41CD25high regulatory T (Treg) cells have been
suggested to play an important role as suppressive reg-
ulators of GVH reactivity [30], their retainment within
allodepleted T cell subsets has not been addressed in
most selective allodepletion (SD) strategies.
In the present study we extended our previously
reported experiments on the depletion of murine
alloreactive T cells by CD95/CD178-mediated activa-
tion-induced cell death (AICD) [31] to human donor-
recipient pairs with complete or partial HLA match.
We demonstrate that substantial CD95-induced
allodepletion can be achieved in human T cells using
either hematopoietic cells or primary keratinocytes as
alloantigen-presenting cells. Residual antiviral and
antileukemic T cells were preserved at significant
numbers within the allodepleted cell subsets. Further-
more, naturally occurring CD41CD251 FoxP31Treg
cells did not appear to be as susceptible to CD95-
mediated AICD as activated T cells, suggesting that
Treg cells might be largely retained by SD via the
CD95/CD178 pathway.
MATERIAL AND METHODS
Cell Lines
The human mutant cell line T2 (174CEM.T2)
and the human CML cell line K562 transfected with
full-length cDNA encoding the HLA-A*0201 allele
[32] were cultured in RPMI 1640 medium (Cambrex
Bio Science, Verviers, Belgium) supplemented with
L-glutamine (2 mM/L), penicillin (100 U/mL), strep-
tomycin (100 mg/mL) (Gibco BRL, Grand Island, NY)
and 10% fetal calf serum (FCS) (Cambrex Bio Sci-
ence). Cell cultures were kept in a water-saturated
atmosphere with 5% CO2 at 37
C.
Peptides
HLA-A*0201-associated peptide epitopes used
herein were Epstein-Barr virus (EBV) BMLF1 peptide280-288 (GLCTLVAML), cytomegalovirus (CMV)
pp65 peptide 495-503 (NLVPMVATV), and a peptide
derived from human Wilms tumor antigen 1 (WT1)
126-134 (RMFPNAPYL). They were synthesized on
solid phase using Fmoc chemistry, purified by re-
versed-phase high-performance liquid chromatography
(HPLC), and characterized by mass spectrometry.
Generation of Human Primary Keratinocytes,
B Cells, and Dendritic Cells
Primary keratinocyte cultures were generated from
5-6 mm2 skin samples derived from skin or foreskin of
patients undergoing surgery. Briefly, the epidermis
was separated from dermis after overnight incubation
at 4C in 2.4 U/mL Dispase II (Roche, Mannheim,
Germany) in phosphate-buffered saline (PBS) contain-
ing 2.5% Gentamycin (Invitrogen-Gibco, Karlsruhe,
Germany) and trypsinized for 30 minutes at 37C to
obtain a single cell suspension. Keratinocytes (KCs)
were then cultured at 37C, 5% CO2 in MCDB 153
(Biochrom AG, Berlin, Germany)/keratinocyte-SFM
medium (Invitrogen-Gibco) mixture (50:50, v/v)
supplemented with 25 mg/mL bovine pituitary extract
(Invitrogen-Gibco) and 100 mg/mL recombinant
epidermal growth factor (Invitrogen-Gibco). Conflu-
ent cultures of KCs were split 1:1 and were expanded
up to 5 to 6 culture passages. In some experiments
KCs were pretreated with 500 IU/mL interferon-
gamma (IFN-g) (ImmunoTools, Friesoythe, Ger-
many) over 3 days prior to use.
Peripheral blood B cells were stimulated using
NIH-3T3 cells stably transfected with human CD40
ligand (CD40L) [33]. CD40L cells were irradiated
(100 Gy) and seeded in 6-well plates (Greiner, Nu¨rtin-
gen, Germany) at 4  105 cells/mL in Dulbecco’s
Modified Eagle Medium/F-12 Nutrient (Gibco BRL)
mixture (50:50, v/v) supplemented with L-glutamine
(2 mM/L), penicillin (100 U/mL), streptomycin (100
mg/mL) (Gibco BRL) and 10% FCS (Cambrex Bio
Science). After 18 to 24 hours, CD40L cells were
cocultured with 2  106/mL peripheral blood mono-
nuclear cells (PBMCs) in Iscove‘s Modified Dulbecco
Medium (Invitrogen-Gibco) supplemented with 10%
(v/v) human AB plasma, 100 U/mL penicillin, 100
mg/mL streptomycin, 100 U/mL Interleukin (IL)-4
(ImmunoTools), 5 mg/mL insulin (Sigma Aldrich,
Deisenhofen, Germany), and 500 ng/mL cyclosporine
A (Sigma, St. Louis, MO). Cultures were replated onto
freshly irradiated CD40L cells in the presence of
cyclosporine A and IL-4 every 3 to 4 days. The number
of B cells was monitored weekly using a CD19 mono-
clonal antibody (mAb) (Beckman Coulter, Miami, FL)
and flow cytometry. Usually, B cell purity exceeded
90% after 2 to 3 weeks.
Dendritic cells (DCs) were generated according to
a protocol of Romani et al. [34] with minor modifica-
tions. Briefly, PBMCs isolated from buffy coats of
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AG) density gradient centrifugation were incubated
at 6.6  106 cells/mL in X-VIVO-15 medium (Cam-
brex Bio Science) on plastic dishes for 2 hours. The
nonadherent cells were removed and the adherent
fraction was cultured in X-VIVO-15 medium in the
presence of 1000 U/mL granulocyte/macrophage
colony stimulating factor (GM-CSF) (Leukomax;
Sandoz, Munich, Germany) and 1000 U/mL IL-4.
50% (v/v) of culture medium supplemented with cyto-
kines was renewed on day 3, and DCs were maturated
on day 6 using a cytokine cocktail containing IL-4
(1000 U/mL), GM-CSF (1000 U/mL), IL-1ß (10
ng/mL; R&D Systems, Wiesbaden, Germany), IL-6
(1000 U/mL; Strathmann AG, Hamburg, Germany),
Tumor necrosis factor (TNF)-a (10 ng/mL; Promo-
Cell, Heidelberg, Germany), and Prostaglandine
(PGE)2 (1 mg/mL; Pharmacia, Erlangen, Germany).
On day 7 to 8, DCs were harvested and used for
allogeneic mixed lymphocyte cultures (MLCs).
Isolation of Primary CD31 T Cells from PBMCs
CD31 T lymphocytes or the CD31 CD81 subset
were positively isolated from PBMCs by immunomag-
netic separation using a T cell isolation kit according
to the manufacturer’s instructions (Miltenyi Biotech,
Bergisch Gladbach, Germany). Purity of the enriched
T cells always exceeded 98% as determined by flow
cytometry.
Stimulation and Depletion of Alloreactive T Cells
via AICD
CD31 or CD31 CD81 T cells isolated from fresh
or thawed PBMCs were first polyclonally activated by
immobilized anti-CD3 mAb (3 mg/mL, Orthoclone
OKT 3, Janssen-Cilag, Neuss, Germany) and soluble
anti-CD28 mAb (1 mg/mL, clone YTH 913.12, Sero-
tec, Du¨sseldorf, Germany) for 3 days followed by 5 to
7 days of culture in cytokine-free X-VIVO-20 medium
in 6-well plates (Greiner). Prestimulated responder
cells (105/well) were then challenged with either irra-
diated (30 Gy) PBMCs, KCs, B cell blasts, or DCs
from HLA mismatched or matched donors at re-
sponder/stimulator ratios of 1:5, 1:2.5, 1:1, and 10:1,
respectively, in MLCs in serum free X-VIVO 20 me-
dium in the absence or presence of agonistic anti-
CD95 mAb (clone CH-11 [IgM]; Immunotech, Mar-
seille, France) in 96-well plate or bulk culture MLCs
for 4 to 5 days. The isotype control mAb was also
from Immunotech.
Efficacy of depletion in MLCs carried out in
96-well plates was determined functionally by mea-
suring proliferative responses using 3H-thymidine
(3HTdR) (0.5 mCi/well; Amersham-Life Science,
Braunschweig, Germany) uptake on day 4 and 5 for
the last 16 to 18 hours of culture. Accordingly,
efficiency and specificity of the depletion procedureperformed in bulk culture MLCs was examined by de-
termining the proliferative response of allodepleted T
cells (105/well) against primary (first party) or irrele-
vant (third party) donor PBMCs in HLA mismatch
pairs and against first party or third party DCs in the
minor histocompatibility antigen (HAg)-mismatch
pairs, respectively, in 96-well MLCs. Radionuclide
incorporation in responder cells was measured on
a b-plate liquid scintillation counter (Wallace, Turku,
Finland). Results represent means of triplicates 6 SD.
Immunophenotyping
Expression of cell surface antigens was examined
using the followingmurine anti-humanmAb and corre-
sponding isotype-matched control mAb in direct
immunofluorescence staining: anti-CD3-FITC, anti-
CD3-PE, anti-CD4-FITC, anti-CD4-PE, anti-CD8-PE,
anti-CD69-PE (all from Immunotech) and anti-
CD25-PE (Miltenyi). Briefly, 1 105 viable cells were
incubated with mAb for 15 minutes at 4C followed by
2 washings with PBS containing 0.5% FCS.
Analyses of CD41 CD251 FoxP31 regulatory T
(Treg) cells before and after allodepletion was per-
formed using a regulatory T cell staining kit (Natu-
Tec, Frankfurt/Main, Germany) according to the
manufacturer’s instructions. Briefly, PBMCs were first
surface labeled with CD4-PE and CD25-APC mAb,
respectively, followed by fixation and permeabiliza-
tion. After blocking with 2% rat serum, cells were
counterstained with anti-human FoxP3-FITC mAb
(clone PCH101).
For all flow cytometry analyses, 10.000 events were
collected after gating of viable lymphocytes by FSC
and SSC signal list mode data in Cellquest Pro
software on a FACS-Calibur instrument (Becton
Dickinson, Heidelberg, Germany).
IFN-g Enzyme Linked Immunospot (ELISpot)
Assay
IFN-g ELISpot assays were performed as recently
described [26]. Briefly, CD31 or CD81 T cells at 105/
well and APCs at 105/well (DCs at 104/well) were
seeded in ELISPOT plates in serum-free X-VIVO
20 medium. T cells without APCs served as controls.
Peptides were added at final concentration of 10-20
mg/mL directly into the wells or were loaded onto
stimulator cells for 2 hours prior to addition of T cells.
After 20 hours of incubation at 37C, IFN-g spots
were visualized and counted using an Axioplan 2 mi-
croscope combined with the computer-assisted image
analysis system KS ELISpot 4.1 (Carl Zeiss Vision,
Hallbergmoos, Germany). Results represent means
of triplicate wells. Depletion efficacy was calculated
by comparing ELISpot results from allodepleted T
cells compared with those from undepleted controls.
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All values are indicated as means 6 SD. Statistical
analysis of data was performed by the Mann-Whitney
U-test. A value of P\ .01 was considered statistically
significant.
RESULTS
Human Alloreactive T Cells Are Efficiently
Depleted by CD95-Mediated AICD
Based on our previous results obtained in murine
bone marrow transplantation models [31] we explored
the CD95-mediated induction of apoptosis in human
activated alloreactive T lymphocytes in vitro. Because
resting human T lymphocytes are resistant to AICD
[35], purified CD31 T cells derived from PBMCs of
healthy donors were first activated by incubation
with anti-CD3 and anti-CD28 mAbs. Preactivated re-
sponders were then cocultured with irradiated major
or minor histoincompatible allogeneic stimulator cells
in bulk mixed lymphocyte cultures (MLCs) over 5 days
either in the presence or absence of agonistic anti-
CD95 mAb.
Following stimulationof TcellswithHLA-incom-
patible DCs (Figure 1A) or CD40L-activated B cells
(Figure 1B) in the presence of anti-CD95mAb, the pro-
liferative alloimmune responsewas reduced to amean of
6.3% 6 9.3% and 10.6% 6 18.1%, respectively, com-
pared to undepleted controls. This decrease of alloreac-
tivity was dependent on the dose of anti-CD95 mAb
showing a maximum depletion efficiency at 200 ng/
mL. In contrast, the isotype matched control Ab did
not affect the alloimmune response (Figure 1A and B).
Furthermore, primary human keratinocytes (KCs)
established from skin biopsies of surgery patients were
successfully used to stimulate alloreactive T lympho-
cytes in HLA-mismatched donor-recipient pairs.
Mean residual alloreactivity was 25% 6 9.5% follow-
ing allodepletion (Figure 1C). Pretreatment of KCs
with IFN-g did not significantly affect the allodeple-
tion results. These data confirmed that depletion of
alloreactive T cells can be achieved using nonpro-
fessional APCs of epithelial origin within the SD
approach [25].
Residual reactivity of allodepleted donor lympho-
cytes was then determined against original stimulator
PBMCs (first party) and found to be strongly reduced
(mean of 7.0% 6 13.5%) compared to undepleted
controls (Figure 1D). However, the strength of
alloimmune responses to HLA-irrelevant third-party
PBMCs remained unaffected after the depletion
maneuver (Figure 1D).
To exclude preferential allodepletion of the CD41
subset within the CD31 T cell responder population,
purified CD81 T lymphocytes were stimulated
with HLA-incompatible DCs in the presence of
anti-CD95 Ab (Figure 2). Again, alloreactivity byCD81 responder cells was reduced to a mean of
22.8%6 9.4%when compared to undepleted controls
as determined by proliferative responses (Figure 2A) or
IFN-g secretion levels of residual allodepleted donor
CD81 T cells stimulated against primary stimulator
DCs (Figure 2B). Moreover, allodepletion to given
HLA-mismatch antigens was specific and did not
significantly affect the anti-third-party alloimmune
response (Figure 2C). Taken together, these results
suggested that both CD41 and CD81 alloreactive
donor T lymphocytes are effectively eliminated by
CD95-mediated SD.
The allodepletion results obtained in HLA-
mismatched MLCs could be confirmed in donor-
recipient pairs with complete genomic HLA match
at high-resolution level. Coculture of donor T lym-
phocytes with HLA-identical DCs (Figure 3A) or B
cells (Figure 3B) in the presence of agonistic anti-
CD95 mAb resulted in a mean reduction of minor
histoincompatibility driven alloreactivity to 10.5% 6
11.1% and 14.4% 6 9.2%, respectively. Moreover,
analyses of residual immunity of allodepleted donor
T cells to first-party and HLA-irrelevant third-party
DCs showed a significant and specific decrease of reac-
tivity towards the original stimulator cells (Figure 3C).
In summary, these results confirmed our previous
findings in murine models [31] and strongly suggested
that SD of human alloreactive donor lymphocytes by
AICD is efficient and specific for given alloantigens
across both HLA or minor histocompatibility antigen
(H1g) barriers.
CMV and EBV-Specific CD81 T Cells Are Retained
after CD95-Mediated Allodepletion
We analyzed the effect of the CD95-mediated
selective allodepletion procedure on the frequency of
antiviral CD81 T cells. PBMCs isolated from HLA-
A*0201-positive healthy donors were first screened in
IFN-g ELISpot assays for memory CD81 T cells rec-
ognizing HLA-A*0201-restricted CMV-pp65 and
EBV-BMLF1 peptide epitopes. Subsequently, T cells
of donors with detectable antiviral T cell memory were
stimulated with irradiated recipient PBMCs isolated
from EBV and CMV-seronegative individuals that
carried HLA-A*0201 as the only matched HLA-
class-I allele. After CD95-mediated allodepletion,
frequencies of spot-forming antiviral T cells were de-
termined within allodepleted cell subsets and were
compared to undepleted allogeneic and autologous
control populations, respectively (Figure 4).
As demonstrated in a total of 3 HLA-mismatched
donor-recipient pairs, CMV-pp65/A*0201-reactive T
cells persisted in allodepleted donor lymphocytes
with a mean frequency of 71.9% 6 6.4% compared
to undepleted controls (Figure 4A). Similarly, EBV-
BMLF1-reactive CD81 T cells were retained
after allodepletion in all 3 HLA-mismatched
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Figure 1. Depletion of alloreactive T lymphocytes by CD95-
mediated AICD. Purified CD31 donor T cells were first activated
with immobilized anti-CD3 and soluble anti-CD28 mAbs for 3 days
followed by 5 days of culture in cytokine-free medium. Activated
T cells were then stimulated in allogeneic MLCs with HLA-
mismatched (A) DCs, (B) B cell blasts, or (C) primary human kerati-
nocytes (KCs) for 5 days in the presence of agonistic anti-CD95 or
isotype control mAbs at indicated concentrations. In some experi-
ments KCs were pretreated with 500 IU/mL IFN-g over 3 days.
(D) Following MLCs, allodepleted T cells were challenged with
PBMCs of the original stimulator cell donors (first-party) or with
irrelevant (third-party) PBMCs inMLCs to determine the specificity
of the depletion procedures. Proliferative responses were measured
by [3H]-thymidine uptake for the last 18 h of incubation on days 3,
4, or 5 of culture. T cells stimulated with autologous DCs, B cells,donor-recipient pairs analyzed (97% 6 16.68%) (Fig-
ure 4B). Interestingly, some undepleted allogeneic
control populations contained increased frequencies
of antiviral CD81 T cells following stimulation with
recipient PBMCs devoid of any detectable reactivity
to CMV-pp65 or EBV-BMLF1 peptides. This may
likely represent bystander activation of antiviral mem-
oryT cells previously observed by us and others [22,36]
or be attributed to increased resistance to cell death
through upregulation of Bcl-2 expression [37].
Allodepleted T Cell Subsets ContainWT1-Specific
CD81 T Cells
In addition to antiviral T cell immunity, we ana-
lyzed whether allogeneic T cell specificities potentially
conferring GVL immune responses would persist at
significant frequencies following CD95-mediated
SD. Because cytotoxic T cells specific for the HLA-
A*0201-binding peptide 126-134 encoded by the
leukemia-associated WT1 antigen can be detected at
low frequencies in PBMC of healthy donors [38], we
investigated the preservation of WT1 peptide-specific
T cells after allodepletion of anti-MHC mismatch
responders. Following stimulation of purified CD31
T cells from HLA-A2-positive WT1-reactive donors
with HLA-A2-matched but HLA-B/C-mismatched
stimulators in the presence of anti-CD95 mAb, re-
maining responders were challenged with WT1 pep-
tide 126-134 loaded onto HLA-A*0201-expressing
TAP-deficient T2 cells. Because K562-HLA-A*0201
transfectants present endogenously processed WT1
and thus elicit strong background reactivity [39], T2
cells were used as APCs in these experiments.
When compared with the frequency of WT1
peptide-specific T cells found in the undepleted
control prior to allogeneic stimulation, WT1 reactiv-
ity in the allodepleted cell subset was detected at
a mean frequency of 84.4% 6 9.0% (Figure 5). This
suggested that donor T cells potentially conferring
WT1-specificGVL reactivity can be retained at signif-
icant numbers after allodepletion by AICD. The ap-
parently increased WT1 reactivity above background
levels observed in this experiment might be explained
by the simultaneous reduction of background reactiv-
ity against T2 cells following allodepletion.
CD41 CD251 FoxP31 Regulatory T Cells Can Be
Retained following CD95-Mediated SD
As CD41CD251 FoxP31Treg cells have been sug-
gested to suppress GVHD-inducing T lymphocytes,
or medium (for KCs) were used as controls (auto control). Data
are given as means6 SD of triplicates and are shown for 1 represen-
tative of 5 donor-recipient pairs. P-values were analyzed between the
most relevant experimental groups. Values \.01 are considered
statistically significant. Asterisk means that the difference between
2 experimental groups was not significant.
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Figure 2. Depletion of alloreactive CD81 T cells by CD95-medi-
ated AICD. PurifiedCD81 donorT lymphocytes were first activated
as described in Figure 1. (A) T cells were then stimulated with HLA-
mismatched DCs in the presence of agonistic anti-CD95 or isotype
control mAbs at indicated concentrations and proliferative alloim-
mune responses were determined by [3H]-thymidine uptake for the
last 18 hours of incubation on day 3 of culture. T cells stimulated
with autologous DCs were used as controls (auto control). (B) Fol-
lowing MLCs with agonistic anti-CD95 mAb or isotype control
mAb at indicated concentrations, 1  105 of allodepleted or un-
treated CD81 T cells/well were challenged with original DCs as
stimulators to examine IFN-g secretion of residual effector cells by
ELISpot assay. (C) IFN-g secretion of 1  105 allodepleted or un-
treated CD81 T cells/well after restimulation with first-party DCs
or HLA-irrelevant third-party DCs as stimulators. Background in
all figures is represented by proliferation or IFN-g spots obtained
from T cells cultured with autologous DCs (auto DC). Data are
given as means6 SD of triplicates and are shown for 1 representative
of 3 donor-recipient combinations. P-values are indicated as de-
scribed in Figure 1.the persistence of this cell type in donor lymphocyte
products appears desirable [30]. Thus, we analyzed
the frequency of Treg cells after SD using the agonistic
anti-CD95 mAb.
Among CD31 T cells isolated from fresh PBMCs
and analyzed for CD4, CD25, and FoxP3 expression,
3.0% of all CD41 T cells were positive for FoxP3
(Figure 6; data on CD25 FoxP3 costaining not shown).
Upon primary stimulation with immobilized anti-
CD3 and soluble anti-CD28 mAbs followed by a rest-
ing period in cytokine-free medium, the frequency of
CD41 FoxP31 Treg cells remained in the same range
(3.1%). Following allostimulation and CD95-medi-
ated SD over the next 5 days, 2.6% of CD41 responder
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Figure 3. Depletion of minor HAg mismatch reactive T lympho-
cytes via CD95-mediated AICD. Preactivated (see Figure 1) CD31
donor T cells were stimulated in MLCs with (A) allogeneic DCs
or (B) allogeneic B cell blasts generated from individuals with full
HLA class I and class II match according to high-resolution typing.
Agonistic anti-CD95mAb was added at 200 ng/mLwhere indicated.
(C) Following MLCs, allodepleted T cells were restimulated with
original DCs (first-party) or irrelevant DCs (third-party) to deter-
mine depletion specificity. Proliferation was analyzed in triplicates as
described in Figure 1. T cells stimulated with autologous DCs were
used as controls (auto control). Data are from 1 representative of 3
donor-recipient pairs. P-values are indicated as described in Figure 1.
Depletion of Alloreactive T Cells by AICD 105cells stained positive for FoxP3 showing a comparable
percentage of double positive cells as before MLCs
(Figure 6). These data suggested that Treg cells defined
by FoxP3 expression remained at reduced but clearly
detectable frequencies after CD95-mediated SD.
DISCUSSION
SD strategies aim at the removal of unwanted
host-reactive T cells from the donor lymphocyte graft
while preserving allogeneic specificities able to gener-
ate beneficial antitumor and antipathogen immune re-
sponses, respectively. Several approaches to selectively
inhibit or deplete alloreactivity have been investigated
in human in vitro systems and murine animal models
[12-26]. However, with some exceptions [20-22,36,
40], a detailed in vitro analysis on the persistence
of T cells with antiviral, immunoregulatory, and, in
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Figure 4.CMV and EBV-specific CD81T cells persist after CD95-
mediated allodepletion. CD31 T cells derived from HLA-A*0201-
positive healthy donors with previous CMV and EBV exposure
were activated in HLA-A*0201-matched allo-MLCs followed by
anti-CD95-induced AICD. T cells obtained from autologous con-
trol PBMCs, or from allodepleted and untreated MLC populations
were then stimulated with K562-HLA-A*0201 transfectant cells
alone (gray bars) or pulsed with the HLA-A*0201-binding CMV-
pp65495-503 and EBV-BMLF1280-288 peptides (black bars), respec-
tively, in IFN-g ELISpot assays. Controls (white bars) represented
T cells that secreted IFN-g spontaneously. Data are presented as
means6 SD of duplicates or triplicates, respectively. One represen-
tative of 3 experiments performed for 3 different CMV-positive (A)
and EBV-seropositive (B) donors is shown. P-values are indicated as
described in Figure 1.particular, potential antileukemic immune functions
following allodepletion remains to be demonstrated.
Based on previous work in murine bone marrow
transplantation (BMT) models [31] we explored an
anti-CD95 in vitro protocol to selectively deplete hu-
man alloreactive T cells from the total pool of donor
lymphocytes. Following stimulation of donor T cells
with HLA-mismatched as well as HLA-matched re-
cipient hematopoietic cells in the presence of agonistic
anti-CD95 mAb, we demonstrated reduction of allo-
reactivity with a mean efficiency of $93% for HLA-
mismatched and $89% for HLA-matched settings,
respectively. In addition, restimulating residual donor
cells with original (first-party) or irrelevant (third-
party) stimulator cells revealed that the depletion was
alloantigen specific. Moreover, significant reduction
of CD81T cell-mediated alloimmune responses could
be demonstrated, strongly suggesting that CD95-
mediated SD does affect both CD41 andCD81 allore-
active donor T lymphocytes.
Polymorphic minor HAgs, expressed either ubiq-
uitously or restricted to cells of the hematopoietic
lineage, are not only regarded as main target structures
for GVH reactivity, but have also been reported to be
important for the induction of GVL immunity [15].
Thus, the retainment of donor T cells reactive to he-
matopoietic minor HAgs within allodepleted donor
lymphocyte grafts would be beneficial for the induc-
tion of specific GVL responses. Skin biopsy-derived
human KCs represent accessable cells of nonhemato-
poietic origin, which can trigger efficient T cell allo-
reactivity [25] and express a comprehensive set of
ubiquitous and lineage-specific minor HAgs [41].
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Figure. 5. WT1-specific CD81 T cells are retained after CD95-
mediated allodepletion. T cells of WT1-positive, HLA-A*0201-
positive healthy donors were activated in HLA-A*0201-matched
allo-MLCs followed by depletion of alloreactivity via CD95-
mediated AICD. CD81 T cells from autologous control, untreated
or allodepleted populations were stimulated with unloaded T2 cells
(gray bars) or with T2 cells pulsed with the HLA-A*0201-binding
WT1 126-134 peptide (black bars) in IFN-g ELISpot assay. Data
are given as means 6 SD of triplicates and are representative of 3
donor-recipient combinations totally analyzed. P-values are indi-
cated as described in Figure 1.
106 U. F. Hartwig et al.Figure 6. CD41 FoxP31 Treg cells are not affected by CD95-mediated allodepletion. The percentages of CD4
1 FoxP31 Treg cells were deter-
mined within fresh PBMCs (d0) and after a preactivation culture period over 6 days (d6) by flow cytometry. Following allodepletion in MLCs
against HLA-mismatched PBMCs, CD41 FoxP31T cells were again measured in the anti-CD95 Ab-treated and isotype control Ab-treated cell
subsets, respectively (d11). Data of 1 representative of 3 donor-recipient combinations are shown.Using KCs as allogeneic stimulator cells we could
demonstrate significant CD95-mediated allodeple-
tion, suggesting that this SD strategy might be feasible
for eliminating reactivity to ubiquitous or epithelial
alloantigens, but simultaneously spare T cells specific
for hematopoiesis-restricted minor HAgs.
Apart from severe GVHD, opportunistic infec-
tions, particularly caused by CMV and, albeit less
frequently, by EBV, remain major causes of morbidity
andmortality after AHSCT [42]. Both CD81CTLs as
well as CD41 T helper cells have been shown to play
a central role in controlling CMV and EBV infections
[42]. Following SD by CD95-mediated AICD, we ob-
served inHLA-A*0201-matched donor-recipient pairs
that within allodepleted donor lymphocytes antiviral
CD81 T cells to both CMV and EBV are retained at
frequencies comparable to levels detected prior to de-
pletion. Similar to previous reports using CD25 and
CD69-mediated SD approaches [20-22,36,40], reac-
tivity to the EBV-BMLF1 peptide within alloantigen
stimulated donor cells was found to be elevated. This
observation might be attributed to bystander
activation acquired during repetitive stimulations of
alloreactive responders resulting in IFN-g secretion
of recently EBV-activated specificities, as T lympho-
cytes derived from healthy donors with reactivities toviruses most likely represent memory-type T cells.
Moreover, virus-specific memory CD81 T cells may
have an increased resistance to cell death as they can
upregulate antiapoptotic genes such as Bcl-2 [37].
There is increasing evidence that donor immunity
toward hematopoiesis-restricted minor HAgs is
important for generating clinically effective GVL
immunity [15,43]. The situation is less clear for
leukemia-associated antigens, which also have been
identified as target structures of donor T cells. Using
WT1 as a model for leukemia-associated antigens, we
investigated the persistence of HLA-A*0201-restricted
WT1 peptide-specific CD81 T cells following allode-
pletion in healthy donors with detectableWT1 reactiv-
ity [38,39]. We demonstrated that WT1-reactive T
cells are largely retained at significant frequencies after
CD95-mediated SD.Taken together, our experimental
data suggest that allodepletion by CD95-mediated
AICD can preserve donor lymphocytes specific for
herpes virus and leukemia-associated antigens.
Finally, we explored the persistence of CD41
CD251 FoxP31 Treg cells usually present at 1%-5%
of total CD41 cells in human peripheral blood [44].
Tregs have been phenotypically defined by constitutive
coexpression of CD4 and the interleukin-2 receptor al-
pha chain (CD25) [45]. However, CD25 is also
Depletion of Alloreactive T Cells by AICD 107expressed by activated T cells, and thus represents an
unreliable marker for Treg cells. FoxP3, encoding
a forkhead/winged helix transcription factor, has been
identified as a key regulatory gene required for the de-
velopment of Treg cells, and therefore, has been used to
define a naturally occurring CD41 Treg population
within PBMCs [46]. However, CD41 CD252 T cells
have also been reported to express FoxP3 and differen-
tiate into Treg cells upon suboptimal activation condi-
tions or in the presence of low doses of antigen [47].
In our study, the frequency of FoxP31 cells de-
tected within the CD41 T cell population remained
stable following short-term polyclonal activation and
3 day resting in the absence of exogenous IL-2. More-
over, the proportion of residual CD41 FoxP31 cells
after CD95-mediated SD was largely comparable to
the frequency detected in the control population on
d0. Supported by the findings that in contrast to their
naive CD41CD252 counterparts Treg cells appeared
to be resistant to IL-2 driven CD95-induced apoptosis
followingTCR-mediated activation [48,49], this result
suggested that Treg cells are not highly susceptible to
allodepletion via the CD95/CD178 pathway. Never-
theless, our data should be interpreted with caution
because of the following reasons: first, although
the percentages of Treg cells might be preserved, the
absolute numbers will most likely be reduced by the
anti-CD95 depletion maneuver in vitro. It should be
kept in mind that efficient suppression of GVHD in
murine models required the adoptive transfer of a sub-
stantial excess of CD41Treg cells [30]. Second, there is
the possibility that a procedure-related reduction of
Treg cell numbers might have been masked by a simul-
taneous increase of FoxP3 expression levels on T cells
that were activated by our in vitro protocol. This as
well as potential pitfalls of Treg cell immunotherapy
in humans [50] prevent us from overstating the
relevance of the Treg cell data shown herein.
Most SD approaches are performed after primary
MLC in which alloreactive donor T cells are activated
by nonmalignant recipient cells over a few days. This
also applies to SD technologies that use anti-CD69
immunomagnetic cell separation [23,24,36] or the
currently described agonistic anti-CD95 antibody
inducing AICD. The comparably short MLC period
followed by SD should facilitate the clinical translation
of such methods, as has already been successfully
accomplished with similar anti-CD25 directed SD
procedures [20-22,27-29]. In contrast, our recently
described anti-CD137 approach is based on the
enrichment of GVL reactivity by repetitive in vitro
stimulations with leukemia cells over 2 to 3 weeks
before SD [26]. Although the CD137-based method
is considerably more complex and laborious compared
to current anti-CD69/-CD25/-CD95 technologies,
such leukemia-sensitized allodepleted T cell lines
might be of considerable value for patients who requirean immediately strong GVL effect, for example,
because of ongoing or threatening leukemia relapse.
In conclusion, this study demonstrates that the
removal of alloreactivity by CD95-mediated AICD is
feasible, and results in efficient allodepletion of human
donor lymphocyte products in vitro, while retaining
substantial numbers of antiviral, antileukemic, and
regulatory T cells. The data confirm our previous
work on depleting alloreactivity in murine models via
the CD95/CD178 pathway [31]. Nevertheless, it
remains unclear from these results wether the observed
allodepletion in the order of 12 log will translate into
significant GVHD reduction following adoptive trans-
fer of manipulated DLI into humans in vivo, as
suggested from our murine studies. Moreover,
efficient allodepletion does not mean that residual
antileukemic T cells will be of sufficient quantity and
quality to prevent leukemia relapse. Expansion of
leukemia-reactive T cell precursors might be accom-
plished by subsequent in vitro stimulations of allode-
pleted T cells with leukemia antigens. For the SD
strategies based on CD95/CD178 and CD137, we
are presently trying to fulfill all prerequisites that are
necessary for future clinical testing.
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